Although the guidelines for pancreatic cancer suggest up-front surgery, data from recent studies are making it clear that neoadjuvant chemotherapy is superior to up-front surgery, particularly with regard to a pancreaticoduodenectomy. Neoadjuvant chemotherapy provides patients with the opportunity to receive the therapy, explains Choti. Read more . . .
Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses the benefit of neoadjuvant chemotherapy in pancreatic cancer.